Madrigal Pharmaceuticals Inc annual earnings per share (EPS) for fiscal TTM was $-12.93, a decrease of 0.6% from $-12.85 in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| EPS (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (EPS) | $-12.93 | $-12.85 | $-21.90 | $-19.99 | $-17.23 | $-14.58 | $-12.78 | $-4.73 | $-2.22 | $-2.54 | $-5.07 | $-40.03 | $-30.62 | $-44.47 | $-37.00 | $-35.15 | $-32.50 | $81.13 | $-96.09 | $-68.45 | $-57.00 |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| EPS (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (EPS) | $-1.99 | $-3.25 | $-2.61 | $-5.08 | $-1.90 | $-3.32 | $-2.71 | $-4.92 | $-7.10 |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More MDGL metrics: Revenue · Gross Profit · Operating Income · Net Income · EBITDA · Free Cash Flow · Shares Outstanding
All MDGL financial statements → Interactive MDGL charts →
About TickerBase · Data methodology & sources · Privacy · Terms